Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25206156 | 0.78 | LMNA (0.47) | MMECA2CA4PKLRGAA | |
| SCHEMBL25206154 | 0.78 | LMNA (0.47) | MMECA2CA4PKLRGAA | |
| SCHEMBL23366213 | 0.76 | ENPEP (0.30) | — | |
| SCHEMBL7898517 | 0.73 | MME (0.46) | MMECA2CA4PKLRGAA | |
| SCHEMBL23967395 | 0.73 | MME (0.46) | MMECA2CA4PKLRGAA | |
| SCHEMBL28910144 | 0.72 | MME (0.45) | MMECA2CA4PKLRGAA | |
| SCHEMBL30826516 | 0.71 | ITGB3 (0.44) | MMECA2CA4MAPTLMNA | |
| SCHEMBL23366205 | 0.69 | — | — | |
| SCHEMBL23366220 | 0.69 | — | — | |
| SCHEMBL21841573 | 0.69 | PKLR (0.37) | MMECA2CA4PKLRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377487-B1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | AusVir Therapeutics Pty Ltd (AU) | 2022-01-12 | — | — | EP | disclosed |
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | MME 14/4885CA2 246/4885CA4 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.